Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering

Lantern Pharma Inc. (NASDAQ:LTRN) (“Lantern”, the “Company” or “we”), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, today announced the closing of its previously announced registered direct offering of 3,669,725…